MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells

Although many epidermal growth factor receptor (EGFR)-mutated lung cancer patients initially benefit from the EGFR-inhibitor erlotinib, all acquire resistance. So far, several mechanisms implicated in resistance have been identified, but the existence of multiple resistance mechanisms in parallel ha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncogenesis
Main Authors: Jakobsen, K R, Demuth, C, Madsen, A T, Hussmann, D, Vad-Nielsen, J, Nielsen, A L, Sorensen, B S
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5520494/
https://ncbi.nlm.nih.gov/pubmed/28368392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/oncsis.2017.17
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados